1. Home
  2. RVPH vs MCHX Comparison

RVPH vs MCHX Comparison

Compare RVPH & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVPH
  • MCHX
  • Stock Information
  • Founded
  • RVPH 2006
  • MCHX 2003
  • Country
  • RVPH United States
  • MCHX United States
  • Employees
  • RVPH N/A
  • MCHX N/A
  • Industry
  • RVPH Biotechnology: Pharmaceutical Preparations
  • MCHX Business Services
  • Sector
  • RVPH Health Care
  • MCHX Consumer Discretionary
  • Exchange
  • RVPH Nasdaq
  • MCHX Nasdaq
  • Market Cap
  • RVPH 88.0M
  • MCHX 84.3M
  • IPO Year
  • RVPH N/A
  • MCHX 2004
  • Fundamental
  • Price
  • RVPH $1.80
  • MCHX $2.07
  • Analyst Decision
  • RVPH Strong Buy
  • MCHX
  • Analyst Count
  • RVPH 5
  • MCHX 0
  • Target Price
  • RVPH $11.40
  • MCHX N/A
  • AVG Volume (30 Days)
  • RVPH 1.6M
  • MCHX 40.1K
  • Earning Date
  • RVPH 11-14-2024
  • MCHX 03-13-2025
  • Dividend Yield
  • RVPH N/A
  • MCHX N/A
  • EPS Growth
  • RVPH N/A
  • MCHX N/A
  • EPS
  • RVPH N/A
  • MCHX N/A
  • Revenue
  • RVPH N/A
  • MCHX $48,594,000.00
  • Revenue This Year
  • RVPH N/A
  • MCHX N/A
  • Revenue Next Year
  • RVPH N/A
  • MCHX $4.63
  • P/E Ratio
  • RVPH N/A
  • MCHX N/A
  • Revenue Growth
  • RVPH N/A
  • MCHX N/A
  • 52 Week Low
  • RVPH $0.60
  • MCHX $1.11
  • 52 Week High
  • RVPH $4.50
  • MCHX $2.40
  • Technical
  • Relative Strength Index (RSI)
  • RVPH 45.36
  • MCHX 60.01
  • Support Level
  • RVPH $1.97
  • MCHX $1.88
  • Resistance Level
  • RVPH $2.14
  • MCHX $2.04
  • Average True Range (ATR)
  • RVPH 0.16
  • MCHX 0.09
  • MACD
  • RVPH -0.02
  • MCHX 0.01
  • Stochastic Oscillator
  • RVPH 29.29
  • MCHX 90.48

About RVPH Reviva Pharmaceuticals Holdings Inc.

Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.

About MCHX Marchex Inc. Class B

Marchex Inc is a conversational analytics and solutions company that helps businesses connect, drive, measure, convert callers into customers, and connect the voice of the customer to their business. It delivers data insights and incorporates artificial intelligence (AI)-powered functionality that drives insights and solutions to help companies find, engage, and support their customers across voice and text-based communication channels. The group enables sales and marketing teams to deliver the buying experiences that today's customers expect. The company generates the majority of its revenues from core analytics and solutions services. The company operates in the United States, Canada, and other countries.

Share on Social Networks: